Martin H. Voss, MD
The combination of the investigational PD-1 inhibitor MEDI0680 and durvalumab (Imfinzi) did not appear to show an improvement in efficacy compared with single-agent nivolumab (Opdivo) in patients with previously treated metastatic renal cell carcinoma (mRCC), according to results of a phase I/II trial (NCT02118337).
Despite these disappointing data, lead study author Martin H. Voss, MD, said that other immunotherapy combinations are still poised to demonstrate superiority to single-agent checkpoint inhibitors in this patient population.
Results showed that there were no significant differences in overall response rate (ORR), progression-free survival (PFS), or overall survival (OS) demonstrated between the 2 arms. Moreover, no patient subgroups appeared to derive additional benefit from the combination versus the monotherapy.
... to read the full story